Cytotoxicity and Mutagenicity of Narrowband UVB to Mammalian Cells

Phototherapy using narrowband ultraviolet-B (NB-UVB) has been shown to be more effective than conventional broadband UVB (BB-UVB) in treating a variety of skin diseases. To assess the difference in carcinogenic potential between NB-UVB and BB-UVB, we investigated the cytotoxicity via colony formation assay, genotoxicity via sister chromatid exchange (SCE) assay, mutagenicity via hypoxanthine phosphoribosyltransferase (HPRT) mutation assay, as well as cyclobutane pyrimidine dimer (CPD) formation and reactive oxygen species (ROS) generation in Chinese hamster ovary (CHO) and their NER mutant cells. The radiation dose required to reduce survival to 10% (D10 value) demonstrated BB-UVB was 10 times more cytotoxic than NB-UVB, and revealed that NB-UVB also induces DNA damage repaired by nucleotide excision repair. We also found that BB-UVB more efficiently induced SCEs and HPRT mutations per absorbed energy dosage (J/m2) than NB-UVB. However, SCE and HPRT mutation frequencies were observed to rise in noncytotoxic dosages of NB-UVB exposure. BB-UVB and NB-UVB both produced a significant increase in CPD formation and ROS formation (p < 0.05); however, higher dosages were required for NB-UVB. These results suggest that NB-UVB is less cytotoxic and genotoxic than BB-UVB, but can still produce genotoxic effects even at noncytotoxic doses.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:11

Enthalten in:

Genes - 11(2020), 6 vom: 11. Juni

Sprache:

Englisch

Beteiligte Personen:

Buglewicz, Dylan J [VerfasserIn]
Mussallem, Jacob T [VerfasserIn]
Haskins, Alexis H [VerfasserIn]
Su, Cathy [VerfasserIn]
Maeda, Junko [VerfasserIn]
Kato, Takamitsu A [VerfasserIn]

Links:

Volltext

Themen:

Broadband UVB
Cytotoxicity
DNA damage
HPRT
Journal Article
Mutagens
Narrowband UVB
Pyrimidine Dimers
Research Support, Non-U.S. Gov't
SCE

Anmerkungen:

Date Completed 19.03.2021

Date Revised 19.03.2021

published: Electronic

Citation Status MEDLINE

doi:

10.3390/genes11060646

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM311240836